How to read an oral GLP-1 script tracker

Fierce Pharma has launched a weekly tracker comparing prescription trends for oral Wegovy and Foundayo. The tracker may show which product is gaining dispensed prescriptions, but it cannot answer which medicine works better, which is safer for an individual, or how many people remain on treatment. A prescription count is a market signal. It is not a clinical outcome^[1].

The products are also not the same molecule. Oral Wegovy contains semaglutide, a peptide-based GLP-1 receptor agonist. Foundayo contains orforglipron, an oral small molecule that targets the GLP-1 receptor^[2]. Both are prescription medicines, and both have official labels that define their indications and safety information. The tracker should be read beside those labels, not in place of them.

What the tracker is measuring

The launch description says Fierce Pharma will use analyst notes and IQVIA data to follow prescription trajectories and changing market share^[1]. In this context, a script is a prescription. Depending on the underlying dataset, a weekly figure may represent prescriptions processed or dispensed through participating channels. The public launch description does not provide enough methodological detail to treat every count as a complete census.

Trend data can still answer a narrow question: is recorded use rising or falling? It can also show whether an early launch advantage shifts between the two brands. Readers following oral semaglutide should resist turning a market-share line into evidence of superior weight loss. Popularity can reflect launch timing, insurance placement, prescriber familiarity, supply, or promotion.

The official DailyMed listings confirm that Wegovy now includes a tablet presentation as well as an injection, while Foundayo is an orforglipron tablet^[2][3]. That basic product distinction is more reliable than shorthand such as 'the two GLP-1 pills.' Our semaglutide mechanism section explains why the molecule itself still matters.

What prescription growth does not prove

More prescriptions do not establish better efficacy. Comparative clinical claims require trials designed to compare outcomes, populations, follow-up periods, and adverse events. A weekly market tracker does none of that. Even if one curve rises faster, the result could describe access and launch execution rather than a difference in treatment effect.

The same limit applies to safety. Labels describe known warnings and adverse reactions based on regulatory evidence, while prescription counts contain no clinical narrative about why someone started or stopped. The semaglutide safety overview should be used for drug-level context. A falling prescription line cannot be assumed to represent intolerance, and a rising line cannot be treated as proof of safety.

Prescription totals also do not reveal persistence. One person may generate several monthly fills, while another may receive one prescription and never refill it. New prescriptions, total prescriptions, paid claims, and unique patients are different measures. A tracker should name the measure before readers compare the curves.

Why launch conditions shape the curves

Oral Wegovy carries an established brand name already associated with injectable semaglutide. Foundayo introduces both a newer brand and orforglipron as its active ingredient. Familiarity may affect early prescribing without settling the longer contest. The DailyMed records identify the current formulations and manufacturers but do not forecast adoption^[2][3].

Coverage can change the shape just as quickly. CMS includes certain oral products in its temporary Medicare GLP-1 Bridge for eligible Part D beneficiaries^[4]. That program has defined criteria, so inclusion does not mean universal access. Readers can check the US semaglutide regulation page for the broader regulatory setting and the semaglutide evidence overview for the distinction between a copay and public spending.

Supply, pharmacy stocking, and insurer decisions can create abrupt changes that look like preference. Marketing can do the same. A useful weekly commentary should separate those events from what the chart itself establishes. If the methodology or channel coverage changes, comparisons across weeks may also need a break in the series.

A better way to read each update

Start by checking whether the update reports new prescriptions, total prescriptions, paid claims, or unique patients. Then look for the time window and any revision to prior weeks. Ask whether the source covers the whole market or a defined channel. Finally, separate the reported movement from the writer's explanation for it. The first may come from data; the second may be interpretation.

Keep product identity in view too. Oral Wegovy is semaglutide, while Foundayo is orforglipron. Findings about one should not be silently transferred to the other. For semaglutide, our evidence summary and US regulatory summary provide more useful clinical and approval context than a leaderboard.

What remains unknown is how early prescription momentum will translate into sustained use, outcomes, and total spending. Those questions need longer follow-up and different data. Anyone considering either prescription medicine should use the official label, read the relevant semaglutide safety context, and speak with a qualified healthcare professional. A market tracker can describe a launch, but it cannot make a treatment decision.